|
Active substance |
pembrolizumab |
|
Holder |
MSD |
|
Status |
Closed |
|
Indication |
First‐Line treatment of metastatic Non‐Small Cell Lung Cancer (NSCLC) in adults whose tumors express PD‐L1 with a ≥50% tumor proportion score (TPS) with no EGFR‐ or ALK‐ positive tumor mutations |
|
Public documents |
|
|
Last update |
09/05/2017 |
Keytruda®
Last updated on 13/09/2024